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Background/aim: Alpha-1 antitrypsin (α1-AT) is a protease inhibitor that is largely released from liver cells. It inhibits neutrophil
elastase and its deficiency increases the risk of developing chronic obstructive pulmonary disease (COPD). The frequency of α1-AT
deficiency has been reported with different prevalence rates in different parts of the world. The most common α1-AT variant causing
α1-AT deficiency is the Pi*Z allele. In this study, we aimed to determine the frequency of the α1-AT genotypic variant in COPD patients
in our country.
Materials and methods: In this study, 196 consecutive COPD patients admitted to our clinic were included. In addition to recording
the demographic data of the volunteers, a dry drop of blood sample was taken from the fingertip for the SERPINA1 genotype study.
Results: One hundred and fifty-eight (80.6%) of the patients were male and the mean age was 56.92 ± 9.84 years. A variant in the
SERPINA1 gene was detected in a total of 14 (7.1%) COPD patients. Pi*ZZ homozygous variant was detected in only 1 (0.51%) patient,
while Pi*MZ was detected in 3 (1.53%) patients. The Pi*S variant was never detected. Various rare heterozygous variants were detected
in 9 (4.6%) patients and a single point mutation was found in one (0.51%) patient. Serum α1-AT levels were significantly lower in
patients with variants compared to the Pi*MM group (p < 0.001).
Conclusion: In this study, which investigated the genotypic α1-AT variant frequency in COPD patients for the first time in our country,
we found that the percentage of homozygous Pi*ZZ patients was 0.51%, but when heterozygous α1-AT gene variant and single point
mutation were included, the frequency was 7.1%. At the same time, while the Pi*S variant was never detected, rare variants were found
more frequently than expected.
Key words: Alpha 1-antitrypsin deficiency, chronic obstructive pulmonary disease, screening, mutation, genome, gene frequency

1. Introduction
Alpha-1 antitrypsin (α1-AT) is a single-chain glycoprotein
consisting of 394 amino acids and 52 kDa in size [1].
The main function of α1-AT encoded by the SERPINA1
gene is to prevent excessive destruction of elastin and
collagen tissue by inactivating elastase and proteinase
3 released from activated neutrophils [2]. Pulmonary
pathologies that occur when the serum level of α1-AT,
which shows this activity most intensely in the liver and
lung, is insufficient, is a characteristic feature of alpha-1
antitrypsin deficiency (AATD). Although emphysema
and chronic obstructive pulmonary disease (COPD) are
the most common conditions that occur in the lung,

bronchiectasis of varying severity may also be seen in
some patients [3].
M-type protease inhibitor (Pi) is the most common
wild-type allele of α1-AT in the general population.
Pi*MM individuals have “normal” plasma levels of
α1-AT (>20 µmol/L), which is sufficient to bind and
inactivate neutrophil elastase. It has been reported that
the common variation among Pi variants in patients
with AATD is Z and S variants. Those with homozygous
genes for the Z allele are expressed as Pi*ZZ and have
plasma α1-AT levels around 5–6µmol/L, while plasma
levels of Pi*SS individuals have approximately 60% of
normal (14–20µmol/L) [1,4]. The risk for lung disease
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due to alpha-1 antitrypsin deficiency depends on the
individual’s α1-AT genotype and α1-AT serum levels as
well as environmental factors. Data on the epidemiology
of remaining missing α1-AT variants, some of which are
associated with significant reduction or absence of plasma
α1-AT, are limited. Because of their low frequency, these
non-Pi*S and non-Pi*Z missing variants are termed ‘rare’
[5].
It has been reported that there is a variable frequency
of AATD in studies conducted in different regions of
the world. For example, while the frequency is 1/5771
in the central region of Europe, it is reported as 1/35702
in the east and 1/3785 in the south [6]. It has been
estimated to be 1/4126 among non-Hispanic whites
in the United States [6]. It is important to know the
regional frequency of AATDs and detect them because
AATD is the most well-known familial cause of COPD
and individualized treatment with α1-AT replacement
can be applied.
There are data on the frequency of AATD, especially
in developed countries of the world. Although there are
few AATD-related studies conducted with the general
population and other patient groups in our country, as
far as we know, there is no study in which the frequency
of AATD was determined in COPD patients. For this
reason, a SERPINA1 genotype study was conducted on
consecutive COPD patients admitted to our hospital to
determine the frequency of AATD in COPD patients in
our country.
2. Materials and methods
This prospective cross-sectional study was conducted
between February 2020 and February 2022 after local
ethics committee approval.
All COPD patients who applied to our clinic in our
center, which is a 3rd level branch hospital of Chest
Diseases and Thoracic Surgery, were evaluated. After
the written consent of the patients was obtained, their
demographic characteristics and comorbidities were
recorded. A dry drop blood sample was taken for the
genotype study. In addition, serum α1-AT levels, alanine
transaminase (ALT), aspartate transaminase (AST) levels,
and 6-min walking distance (6-MWT) were recorded.
The patients were recorded as emphysema-predominant,
chronic bronchitis-predominant, and mixed-type COPD
based on their clinical and radiological features.
We used serum samples and dried blood spot
(DBS) samples (AlphaKits® GE Healthcare Ltd, Cardiff,
CF147YT, UK) for screening and testing for AATD.
The genotype study was conducted at the Progenika
Biopharma laboratory in Spain. Pulmonary function
tests (PFTs) were performed by using the Sensormedics
model 2400 (Yorba Linda, CA, USA) spirometry device,

and according to the American Thoracic Society (ATS)
guidelines [7].
2.1. Statistical analysis
Analysis of the data was carried out using the SPSS 25
package program. Frequency and percentage values
are presented for qualitative variables. The conformity
of the data to the normal distribution was tested with
the Shapiro-Wilk test. While the arithmetic means and
standard deviation values are presented for the variables
conforming to the normal distribution, the median,
minimum, and maximum values are presented for the
variables not conforming to the normal distribution. In
comparisons between two-category qualitative variables
and quantitative variables; an independent sample t-test
was used if parametric test assumptions were met, MannWhitney U test was used if parametric test assumptions
were not met. Type I error rate was taken as 0.05 in the
study.
3. Results
A total of 196 COPD patients, of which 158 (80.6%) were
male, were included in the study consecutively. The mean
age of the volunteers was 56.92 ± 9.84 years. Considering
their smoking history, 39 patients (19.9%) had never
smoked. In patients who were active smokers (25.5%)
or quit smoking (54.6%), the mean duration of smoking
was 35 (min-max 1–120) pack years. Ninety-three
(47.4%) patients had comorbid diseases. Demographic
characteristics, comorbidities, smoking history, pulmonary
function tests, ALT, AST, 6-MWT results of the patients
are given in Table 1.
A variant in the SERPINA1 gene was detected in
14 (7.1%) of the patients. While Pi*ZZ homozygous
mutation was detected in only 1 (0.51%) patient, various
heterozygous anomalies were detected in 12 (6.12%)
patients. A single-point mutation was detected in one
patient (Table 2). In the comparison made between COPD
patients with and without a variant in the SERPINA1 gene,
there was a statistical difference between serum α1-AT
levels, but no difference was found in other parameters
(Table 3).
However, while the mean serum α1-AT level was 146
mg/dL in Pi*MM patients, it was 100 mg/dL when all
variants were included, and 119 mg/dL when Pi*MZ and
Pi*ZZ were excluded, which was statistically significant
(respectively p =< 0.001 and p = 0.025). In addition, it was
determined that there was no difference between COPD
patients with and without variants in the SERPINA1 gene
in terms of emphysema-predominant, chronic bronchitispredominant, and mixed COPD (0.462). The HRCT
section of the patient with a homozygous ZZ variant is
presented in the figure.
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Table 1. Demographic, basic laboratory, and functional parameters of the patients.
f (%)
Gender
Male

158 (80.6)

Female

38 (19.4)

Comorbidity
No

103 (52.6)

Yes

93 (47.4)

DM

24 (12.2)

HT

31 (15.8)

ILD

4 (2)

CHF

8 (4.1)

CVD

1 (0.5)

Sleep apnea syndrome

1 (0.5)

Ischemic heart disease

22 (11.2)

Others

40 (20.4)

Smoking status
Nonsmoker

39 (19.9)

Smoker

50 (25.5)

Ex-smoker

107 (54.6)

Package/year med (minAge
Serum α1-AT level

max)

35 (1–120)
𝑥´ ± 𝑆𝑆/Med (min-max)
56.92 ± 9.84

144 (32–237)

AST

19 (7–74)

ALT

18 (4–95)

FEV1

1.64 (0.33–4.81)

%FEV1

55 (12–130)

FVC

2.51 (0.84–6.44)

%FVC

71.34 ± 22.22

FEV1/FVC

0.65 ± 0.19

TLC

6.85 (3.2–11.2)

%TLC

38.55 ± 57.81

RV

4.4 (0.04–9.4)

%RV

97.22 ± 130.85

6-MWT

365 (2.3–700)

DM: Diabetes mellitus, HT: Hypertension, ILD: Interstitial lung disease CHF: Congestive
heart failure, CVD: Cerebrovascular disease, AST: Aspartate aminotransferase, ALT: Alanine
aminotransferase, FEV1: Forced expiratory volume in 1 s, FVC: Forced vital capacity, TLC: Total
lung capacity, RV: Residual volume, 6- MWT: 6-min walk test
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Table 2: SERPINA1 genotypic distribution of volunteers.
Genotype

n (%)

Pi*MM

182 (92.9 %)

Pi*MMalton

3 (1.53 %)

Pi*MZ

3 (1.53%)

Pi*Mprocida

1 (0.51%)

Pi*MI

3 (1.53%)

Pi*MPlowel

2 (1.02%)

Pi*ZZ

1 (0.51%)

Single point mutation (GRCh38) g.94378611

1 (0.51%)

Table 3. Comparison of laboratory and functional parameters between those with and without variants in the SERPINA1
gene.
Variant (-)

Variant (+)

U/t

p

Serum α1-AT level

146 (32–237)

100 (37.6–164)

298U

<0.001*

AST

21.05 ± 9.76

20.09 ± 6.44

0.32

0.749

ALT

20.63 ± 12.06

23.18 ± 10.53

–0.684 t

0.495

FEV1

1.74 ± 0.88

2.11 ± 1.23

–1.39

0.166

%FEV1

55.88 ± 24.43

67.28 ± 37.64

–1.072

FEV1/FVC

0.65 (0.23–1.76)

0.64 (0.33–1.24)

769.5 U

FVC

2.68 ± 1.03

FVC%

70.69 ± 21.38

TLC
%TLC

t

t
t

0.303
0.289

2.92 ± 0.98

–0.817

t

0.415

78.58 ± 30.2

–0.921 t

0.373

6.44 ± 1.91

8.35 ± 4.04

–1.237

0.231

1.23 (0.55–158)

82.42 (0.84–164)

16 U

RV

4.53 ± 1.95

6.42 ± 4.21

–1.194

%RV

2.8 (0.96–355)

261 (98–424)

7U

6-MWT

366.28 ± 194.89

253.25 ± 213.02

1.05

t

0.719
t

0.247
0.151

t

0.305

Figure. In the axial and coronal sections of the tomography of a patient with alpha 1 antitrypsin
deficiency, more prominent diffuse emphysema is seen in the lower lobes.
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4. Discussion
COPD is a chronic respiratory disease that has risen to
the top of the list of diseases that cause mortality in recent
years. Well-known environmental risk factors for COPD
include air pollution, particulate matter, and prolonged
exposure to irritating gases, particularly cigarette smoke.
In addition to environmental factors, genetic factors also
play a role in the development of COPD, and AATD is the
best known genetic factor [1]. Therefore, the World Health
Organization reported that all individuals with COPD
should be evaluated for AATD, regardless of smoking
history and phenotype [8].
Alpha-1 antitrypsin is a major lung serine proteinase
inhibitor and protects the lung parenchyma from
neutrophil-associated proteolytic degradation. In case
of insufficient serum level or function, COPD is thought
to occur with the contribution of other environmental
factors. The first cases of AATD deficiency were reported
in 1963 by Laurell and Eriksson in five individuals, three
of whom had significant emphysematous lung disease
[9]. In other studies, conducted later, it was found that
COPD generally has an earlier onset in α1-AT deficiency
and panlobular emphysema, which is dominant at
baseline, develops [2]. Therefore, the COPD pattern
with predominant baseline and prominent panlobular
emphysema has been accepted as the classical clinical
phenotype. In previous years, those with more classical
phenotypes and severe lung disease were investigated for
α1-AT. However, current guidelines suggest that all COPD
patients should be checked for α1-AT levels, regardless
of age, smoking status, and COPD severity, since current
information shows that AATD can also occur in those
who do not have the classical phenotype. In our cases who
were homozygous and heterozygous for α1-AT deficiency,
there was no clinically significant difference from other
COPD cases, except that the patient with homozygous
Pi*ZZ was relatively younger. In addition, no statistically
significant difference was found in terms of emphysema
or chronic bronchitis-predominant COPD between our
patients with and without variants, in line with the current
recommendations. However, our patient with Pi*ZZ
homozygous was emphysema dominant type.
The frequency of AATD has a different prevalence in
various countries of the world. Previously, Blanco et al. in
the study, in which 224 cohorts from 65 countries were
evaluated, Pi*Z and Pi*ZZ were the highest frequency and
prevalence in the Atlantic and coastal regions of Europe,
while it was decreasing gradually in Eastern Europe, and
Asia, it was moderate in Pakistan and Thailand. It has been
shown to nearly disappear in Asian regions. Moderate Pi*Z
values were detected in some parts of East Africa, while
very low or no Pi*Z values were found in the rest of Africa
[6]. In our country, there is only one study in which the
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serum α1-AT level of COPD patients was studied before
[10]. Apart from this, there are a limited number of studies
conducted on patients with interstitial lung diseases (ILD)
and in the pediatric age group [11,12]. To our knowledge,
our study is the first study in our country with genotypical
AATD screening results in unselected COPD patients
admitted consecutively.
In the study conducted by Simsek et al., using serum
samples collected from 1203 healthy individuals in our
country, the allele frequencies by isoelectric focusing
method were 96.8% for Pi*MM, 0.7% for Pi*MZ, 0.6% for
Pi*MS, 0.5% for Pi*MF and Pi. *M? (unidentified variants
with available standards) were reported as 1.4% [13]. As
a result of this study, it was calculated that 7256 people in
our country should have Pi*ZZ disease. The only study we
could find in Turkey regarding α1-AT deficiency in COPD
patients was the study by Perincek et al. in which serum
α1-AT levels were screened in COPD patients [10]. In this
study, serum α1-AT level was measured in COPD patients
without genotypic analysis, and its relationship with the
COPD stage was examined. As a result, it was determined
that the serum α1-AT level was below the reference value
in only one of the 243 patients admitted to the hospital,
and the serum α1-AT level increased in direct proportion
to the stage of COPD. In our study, the variant was detected
in 14 (7.1%) of the patients who applied to our clinic
consecutively, in the gene analysis performed. Among
these variants, only one patient had a Pi*ZZ homozygous
mutation, Pi*MZ, Pi*MMalton, and Pi*MI variants were
detected in three patients, each one with Pi*MProcidia, a
total of 12 patients with various heterozygous anomalies,
and one patient with a single nucleotide polymorphism
was detected. The patient with Pi*ZZ was 44 years old and
α1-AT replacement therapy was started.
The normal allele for Alpha 1 antitrypsin is Pi*MM. So
far, more than 120 SERPINA1 mutations have been reported
in the literature, and about 40% of them have been reported
to cause AATD [14]. The most common deficiency alleles
are Pi*S and Pi*Z, which encode abnormal proteins that
polymerize in the liver. The normal genotype, Pi*MM, is
found in approximately 80%–95% of the population, while
almost all of the rest of the population consists of variants
(Pi*SS, Pi*MZ, Pi*SZ, and Pi*ZZ) that are a combination
of the M, Z, and S alleles [1]. The epidemiology of other
variants, some of which are associated with significant
reduction or absence of plasma α1-AT, is poorly known
and due to their low frequency, these non-S and non-Z
variants are termed “rare” [5]. There are approximately 25
rare deficiency alleles associated with reduced serum α1AT levels and 25 null alleles associated with undetectable
amounts of serum α1-AT levels [15]. While the prevalence
of missing genotypes other than common PI*ZZ or PI*SZ
among individuals with AATD in Italy was 11%, the
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prevalence of missing genotypes other than PI*MZ was
reported to be 15% in individuals with moderate AATD
[16]. In Portugal, among those with AATD deficiency, a
remarkable ratio of hetero- or homozygous rare alleles and
null alleles were detected in 9.5% of cases [17]. In a recently
published review, it was reported that a large number of
mutations could be detected, and rare mutations could
be detected in up to 17% of clinical cases in studies, but
they were usually detected at much lower frequencies [18].
In this study, the Pi*S allele, one of the most common
variants, was not detected in any of the patients. However,
among all variants detected, heterozygous Pi*MZ, Pi*
MMalton, and Pi* MI alleles were equally numerous, with
three each (21.4%). In addition, Pi*MPlowel was detected
in 2 (14.2%) patients and Pi*Mprocida in 1 (7.1%) patient.
Alleles named “rare” in our study were found to be more
common than previously reported rates in other studies.
The reason why the Pi*S variant was never detected and the
expected number of rare variants could not be explained.
Although the available data are not sufficient to generalize
the frequency of rare variants in our country, our present
findings clearly reveal the need for more extensive studies
in this area.
During our study, full gene sequencing was requested
in a 40-year-old female patient with COPD accompanying
bronchiectasis and previous pulmonary embolism,
because of GOLD stage IV. Sequencing of SERPINA1
(NM_001127701.1) full gene was carried out and the
following variant is detected: Status Heterozygous, Genome
position (GRCh38) g.94378611 was detected. However,
serum α1-AT level was measured three times during
stable periods and was found to be normal. In previously
published studies, no direct literature information
indicating AATD deficiency with this mutation could be
reached.
The precise determination of the risk of developing
COPD in those with heterozygous Pi*MZ and the
contribution of environmental effects such as smoking
continue to be investigated. The consensus is that smoking
increases the risk for impaired lung function and the
development of COPD in those with the heterozygous
variant. A longitudinal study showed that individuals with
the Pi*MZ genotype had a slightly greater annual reduction
of FEV1 (25 vs. 21 mL/year, p = 0.048) compared with
those with the Pi*MM genotype. In addition, the odds
ratio was found to be 1.3 for the development of airflow
obstruction in Pi*MZ heterozygotes compared to normal
Pi*MM homozygotes [19]. All of the heterozygous patients
in our study had a history of smoking. For this reason,
clear data could not be presented on whether smoking or
not smoking contributes to the development of COPD.
In the presence of Pi*Z, the most common and most
important variant, a low serum α1-AT level is the expected

result. However, in the presence of rare variants, the
exact results of serum α1-AT levels are not known. In a
study conducted in Italy, rare mutations were found in 22
patients in the screening of 200 patients with respiratory
pathology, and serum α1-AT levels were found to be low
in these patients [20]. Similarly, in our study, there was a
statistically significant difference in serum α1-AT levels
between those with Pi*MM and both all variants and
other rare variants (except Pi*ZZ and Pi*MZ). However,
a statistical comparison between rare variants could not
be made due to the insufficient number of rare variants.
Therefore, an off-label application was made in 2 of our
heterozygous patients due to low serum α1-AT levels and
replacement therapy was started.
In clinical practice, more than 95% of severe AATD
cases are associated with the Pi*ZZ genotype, some of them
may occur with liver-related diseases in childhood, COPD
may develop at later ages, especially in the case of cigarette
exposure, and less frequently neutrophilic panniculitis,
polyangiitis granulomatosis, and hepatocarcinoma have
been reported [21]. Accumulation of α1-AT protein in
hepatocytes can be seen in some variants, most commonly
Pi*Z and Pi*MMalton alleles, in which case there is an
increased risk of liver disorders such as neonatal hepatitis,
cirrhosis that may occur in childhood or adulthood, and
hepatocellular carcinoma [22]. In our study, liver enzymes
of alanine transaminase and aspartate transaminase levels
were recorded in patients who applied for this reason, but
no difference in liver enzymes was found between patients
with homozygous or heterozygous variants and those with
normal variants. In the patient with homozygous Pi*ZZ,
additional abdominal ultrasonography was performed and
no significant abnormality was detected. Volunteers were
also compared in terms of functional parameters, but no
difference was found between pulmonary function tests
and 6-min walk tests between patients with homozygous
and heterozygous variants and those with normal variants.
However, as expected, serum α1-AT levels were found to
be lower in patients with variants.
One of the limitations of this study is that the number
of patients is not at a level to reflect the whole country. In
addition, since it is single-centered, it will not be able to
show possible differences between regions.
In conclusion, in this study, which investigated the
genotypic AATD frequency in COPD patients for the
first time in our country, we found that the frequency of
homozygous and heterozygous AAT gene variants was
higher than we thought. Also, while the Pi*S variant was
never detected, rare variants were found more frequently
than expected. This study shows us that AATD deficiency
should always be kept in mind and investigated in COPD
patients and that similar studies should be conducted on a
larger scale in our country.
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